Chemical control of protein secretion using a small molecule approach provides a powerful tool to optimize tissue engineering strategies by regulating the spatial and temporal dimensions which are exposed to a specific protein. These results suggest that chemically controlled FGF-2 secretion can significantly increase bone formation by ASCs in vivo. This study represents a novel approach towards refining protein delivery for tissue engineering applications.
Chemical control of protein secretion using a small molecule approach provides a powerful tool to optimize tissue engineering strategies by regulating the spatial and temporal dimensions which are exposed to a specific protein. We placed fibroblast growth factor 2 (FGF-2) under conditional control of a small molecule and demonstrated greater than fifty-fold regulation of FGF-2 release as well as tunability, reversibility, and functionality in vitro. We then applied conditional control of FGF-2 secretion to a cellular-based, skeletal tissue engineering construct, consisting of adipose stem cells (ASCs) on a biomimetic scaffold to promote bone formation in a murine critical-sized calvarial defect model. ASCs are an easily harvested and abundant source of postnatal multipotent cells and have previously been demonstrated to regenerate bone in critical-sized defects.
These results suggest that chemically controlled FGF-2 secretion can significantly increase bone formation by ASCs in vivo. This study represents a novel approach towards refining protein delivery for tissue engineering applications.
As tissue engineering aims to mimic endogenous processes of development and regeneration, the ability to provide cells with the appropriate stimuli at the proper location and time is indispensable for designing such systems (1, 2) . Chemical control of protein secretion provides a rapid, dose-dependent, and reversible modality to do so, overcoming many of the inherent shortcomings of current methods used to deliver proteins. Tissue engineering has relied heavily on scaffolds as delivery vehicles of recombinant signaling factors (3, 4) . This method is limited by release kinetics from the scaffold. Gene therapy, be it viral, naked DNA, or in concert with celltherapy, offers more consistent levels of signaling factors to the tissue engineering milieu (5-7). However, continuous exposure of a signaling factor is not ideal for the complexity of tissue formation and implies safety concerns as there is not a mechanism to remove what is often a potent growth factor. Chemical control of signaling factors provides a spatiotemporal means to regulate protein levels via systemic administration of a small molecule. We accomplished this regulation by genetically fusing a protein of interest to a small, unstable protein domain, termed a destabilizing domain.
The destabilizing domain confers its instability to its fusion protein partner, resulting in constitutive degradation of the fusion protein. A highly specific small molecule, Shield-1, can rescue the fusion protein from degradation (8) (9) (10) . Engineering cells to secrete such fusion proteins allows for spatial and temporal control of signaling factor exposure in live animals. We applied this technology in one of the most complex in vivo settings, cell-based tissue engineering. Skeletal defects arising from resection of malignancy, trauma, chronic maladies, and congenital defects represent a burgeoning biomedical burden that stands to benefit from tissue engineering advances as the population grows and ages. Regeneration of large bone defects using a cell-based tissue engineering approach would improve current treatment modalities, avoiding the introduction of foreign materials or the morbidity associated with autologous bone grafting, the two current mainstays of therapy (11) . In this study, we demonstrated the regeneration of criticalsized skull defects in mice via chemical control of fibroblast growth factor 2 (FGF-2) exposure to adipose stem cells (ASCs). ASCs, isolated from subcutaneous fat of both mice and humans, have previously been described to clonally possess the potential to differentiate along mesodermal lineages (12) (13) (14) .
Our laboratory has previously regenerated critical-size calvarial defects in mice using ASCs, an attractive cell candidate for autologous use in the clinical realm because of their abundance in adipose and ease of harvest from subcutaneous tissue (15) . FGF-2 has been demonstrated both in development and healing to be an important regulator of bone formation (16) (17) (18) (19) . Furthermore, FGF-2 has been demonstrated to increase the proliferation of mouse ASCs while maintaining their potential for osteogenic differentiation (20) (21) (22) .
We engineered feeder cells to be capable of secreting an FGF-2 fusion protein under a regulation system driven by the presence of the synthetic ligand, Shield-1.
Shield-1 stabilizes a protein destabilizing domain (DD) that has been genetically fused to FGF-2 (DD-FGF2). Regulation of FGF-2 release with the systemic delivery of Shield-1 was used to affect the fate of ASCs to increase murine calvarial healing (Fig. 1A) .
EXPERIMENTAL PROCEDURES
Cell Culture and Harvest-All experiments followed protocols approved by the Administrative Panel on Laboratory Animal Care at Stanford University. The MC3T3 E1 cell line (ATCC) was cultured in alpha MEM with 10% fetal bovine Serum (Invitrogen), 2 mM glutamine, 100 U/ml penicillin, and 100 μg/mL streptomycin.
Adipose stem cells (ASCs) were harvested from the inguinal fat pads of two month old GFP FVB mice as previously described (15) . Excised fat pads were washed in dilute betadine and mechanically minced in cold PBS. The minced fat pads were subjected to 0.075% Type II collagenase (Sigma) digest at 37 ºC for 30 minutes. DMEM with 10% FBS was used to neutralize the digest. This neutralized digest was then centrifuged and the resultant cell pellet passed through a 100 um filter and plated. ASCs were cultured in DMEM with 10% FBS (Invitrogen), 2 mM glutamine, 100 U/ml penicillin, and 100 μg/mL streptomycin. Only first and second passage ASCs were used for in vitro and in vivo experiments.
The cDNA of the low molecularweight form of FGF-2 was cloned into pBMN iBlasticidin after the IL-2 leader sequence and FKBP L106P destabilizing domain. The ФNX ecotropic packaging cell line was transfected with this construct using Lipofectamine 2000 (Invitrogen). Viral supernatants were harvested and used to infect MC3T3 E1 cells with 4 μg/mL polybrene for 4 hours at 37 ºC. Infected cells were then selected with 5 μg/mL Blasticidin (Invitrogen) for 10 days and are termed DD-FGF2 cells.
Quantification of Secreted DD-FGF2-Serum-free media used to culture DD-FGF2 cells were assayed for secreted FGF-2 levels using the basic FGF Quantikine ELISA kit (R & D). Serum free media was collected from cell cultures of DD-FGF2 cells and concentrated ten-fold using Centricon filters (Millipore). Aliquots of the concentrated media were then incubated in 96-well microplates coated with a mouse monoclonal antibody against FGF-2.
Serial diluted samples of recombinant FGF-2 were also incubated in separate wells for a standard curve. Samples were incubated at 4 °C overnight and subsequently color developed.
Optical density of each sample was then measured at 450 nm. All samples were performed in duplicate.
Chemotaxis AssaySix-well transwell cell culture chamber plates (Corning Costar) were utilized for the chemotaxis assay. For this experiment, transwell polyester inserts with a pore size of 8 μm, which would allow cells seeded on the top surfaces of the inserts to migrate through to the bottom surface. Cells were seeded at a density of 40,000 cells per well. Mouse GFP ASCs were seeded in the transwell inserts and DD-FGF2 cells were seeded in the bottom wells.
For the treatment group, cells were exposed to 3 μM Shield-1. Control groups included ASCs cultured alone and ASCs cultured with DD-FGF2 cells but not treated with Shield-1. Six hours after initiating treatment, the top surface of the transwell inserts were wiped clean with cotton applicators and fluorescence micrographs were acquired using the GFP filter to detect mouse GFP ASCs which had migrated though the 8-μm pores. Quantification was performed by counting the number of cells per high power field on five random fields.
Cell ProliferationSix-well transwell cell culture chamber plates were utilized for proliferation assays. Mouse GFP ASCs were seeded at a density of 40,000 cells/well of the six-well plates. DD-FGF2 cells were seeded at an equal density onto the transwell polyester inserts with a pore size of 0.4 μm. This pore size would allow diffusion of soluble factors between DD-FGF2 cells and mouse GFP ASCs, but prevent migration of the two cell groups towards each other.
Treatment groups included co-cultured cells treated with 0.5 μM and 1.0 μM of Shield-1. Control groups included ASCs co-cultured with DD-FGF2 cells but not treated with Shield-1, ASCs cultured alone without Shield-1 treatment, and ASCs cultured alone with 1 μM Shield-1 treatment. ASCs were trypsinized on days 2, 4, 7, and 10 after initiating co-culture and cell counting via a hemacytometer performed in triplicates.
Western Blot AnalysisFor phosphorylated Erk1/2 detection, whole cell lysates of mouse ASCs were obtained by treating cells with cold lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 25 mM NaF) containing 1 mM orthovanadate and protease inhibitor cocktail (SigmaAldrich). Fifty micrograms of protein per well were loaded on a 12% Tris-glycine SDS-polyacrylamide gel (Bio-Rad) and transferred to an Immobilon-P membrane (Millipore).
For phosphorylated Erk detection, a rabbit polyclonal anti-phosphoErk antibody 1:1,000 (Cell Signaling Technology) was used. Non-phosphorylated Erk proteins were detected with α-ERK-1/2, C-14 mouse monoclonal antibody 1:400 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
A horseradish peroxidaseconjugated α-rabbit antibody (HRP) 1:10,000 was used as secondary antibody. Immunoblotted products were visualized by enhanced chemiluminescence substrate (Amersham Biosciences, UK). α-tubulin antibody was used to control for equal loading and transfer of the samples. Bands of the phosphorylated or nonphosphorylated proteins in the immunoblots were normalized with the loading controls (α-tubulin). For densitometric analysis of immunoblotting, bands were scanned and quantified using Image J (NIH).
Critical-Sized Defect Repair-All experiments followed protocols approved by the Administrative Panel on Laboratory Animal Care at Stanford University. DD-FGF2 cells were treated with 4 ng/mL of mitomycin for 45 minutes to render them proliferation incompetent. A 1:2 mixture of these DD-FGF2 cells (50,000 cells) and mouse GFP ASCs (100,000 cells) were then resuspended in 20 μl of growth media and seeded onto 4-mm apatite-coated polylactic co-glycolic acid scaffolds.
Cells were allowed to adhere to the scaffolds for 24 hours prior to implantation into animals.
Critical-sized calvarial defects (4 mm) were created in non-suture associated parietal bone of 60-day-old skeletally mature nude CD-1 mice (4-6 animals/group).
After clearing away pericranium from the parietal bone, 4 mm circular defects were trephined using a highspeed dental drill. Great care was taken to avoid injury to the dura mater underlying the defect. Seeded scaffolds were placed within the defects and the overlying skin closed with 5-0 Vicryl sutures (Ethicon).
Experimental groups for the animals included mice implanted with both ASCs and FGF-2 DD cells which were either treated with intraperitoneal injections of Shield-1 every other day for 12 weeks (Continuous Group), every fourth day for the first 12 weeks (Pulsatile), every other day for the first 3 weeks (Early Group), or every other day during weeks 4-6 (Middle). Control groups included animals which received no Shield-1 treatment and were implanted with empty scaffolds or scaffolds seeded with ASCs and DD-FGF2 cells. A final control group included animals implanted with scaffolds only seeded with DD-FGF2 cells, which were treated with Shield-1 continuously over a 12 week period. We did not include as a control group animals implanted with ASCs alone and not treated with Shield-1, as bone regeneration has previously been demonstrated by our laboratory.
Shield-1 Formulation and DeliveryShield-1 (Cheminpharma) was formulated in 50% N,N-Dimethylacetamide and 50% of a 9:1 PEG-400:Tween-80 mixture. Shield-1 was administered intraperitoneally at 6 mg/kg.
Analysis of Bone Regeneration-
Mice underwent CT scans of their skulls at time of implantation, week 1, week 2, week 4, week 8 and week 20 on the CTI MicroCT (CTI) at an x-ray voltage of 80 kVP and an anode current of 450 μA. A resolution of 40 μm was obtained, with 144 steps over a 360 degree rotation. X-ray data reconstruction and analysis was performed using GEHC Microview (GE Healthcare). Each animal was also scanned with a reference bar consisting of air, water, and hydroxyapatite of standard concentrations.
CT unit measurements were made over these standard materials. A standard curve was created from these measurements, plotting CT units versus hydroxyapatite concentration. CT unit measurements were then made over a volume of interest fashioned around the scaffolds. Hydroxyapatite concentrations were then calculated from these CT unit measurements using our standard curve.
At 2 and 20 weeks, calvaria were harvested and fixed in neutral buffered formalin for 24 hours. The calvaria were then decalcified in 19% EDTA, processed, and embedded into paraffin wax for sectioning. Bone formation was evaluated by pentachrome staining of 8 um thick sections. All stained slides were imaged using a Zeiss Axioplane Microscope.
FGF-2 and proliferation cell nuclear antigen (PCNA) immunohistochemistry was performed after rehydrating paraffin sections of the skulls by incubating in the primary antibody (1:500) overnight at 4 °C (Abcam). After serial washes of the slides in PBS with 0.5% Triton-X, slides were incubated in a horseradish peroxidase linked secondary antibody.
After color development, photographs were taken using the Zeiss Axioplane Microscope.
RESULTS

Chemical control of FGF-2 in vitro-
A destabilizing domain, based on the mammalian FKBP12 protein, was genetically fused between an endoplasmic reticulum (ER) targeting sequence for the human interleukin 2 gene and human FGF2 (DD-FGF2) (23) . Although endogenous FGF2 is secreted non-canonically, targeting it to the ER has been known to increase the efficiency of secretion (24) . The DD-FGF2 construct was retrovirally transduced into MC3T3 E1 pre-osteoblasts and stable cells carrying the transgene were made by drug selection (DD-FGF2 cells). We exposed these cells to a range of Shield-1 concentrations and used ELISA to measure the amount of secreted FGF-2. We found an increase in the amount of DD-FGF2 secreted in response to increasing concentrations of Shield-1 treatment. This effect reached a plateau approximately fifty-fold above background with Shield-1 treatments above one micromolar concentration (Fig. 1B) .
To demonstrate the reversibility of this system in controlling DD-FGF2 secretion, we used ELISA to serially measure secreted DD-FGF2 at 8-hour intervals in response to varying doses of Shield-1 exposure. We began with 0.5 μM of Shield-1 treatment and found peak secretion of DD-FGF-2 secretion to occur approximately 8 hours later. After removal of Shield-1, we found that DD-FGF2 levels returned to baseline levels 8 hours later. When these same cells were exposed to 2 μM Shield-1, approximately twice the amount of DD-FGF2 was secreted, which similarly tapered down when this higher concentration of Shield-1 was removed (Fig.  1C) .
Secreted DD-FGF2 protein is functional-We ascertained the functionality of the secreted fusion protein in vitro, using proliferation and chemotaxis of mouse ASCs co-cultured with DD-FGF2 cells. To assess the chemotactic effects of DD-FGF2, we seeded ASCs on transwell inserts with 8 μm pore size, a pore size which allowed migration of cells across the membrane, and placed these over wells of culture plates seeded with DD-FGF2 secreting cells. A significantly higher number of mouse ASCs migrated through the transwell membrane towards the DD-FGF2 producing cells in groups treated with Shield-1 as compared to control groups (Fig. 1D) .
Using a similar transwell apparatus, we assessed the proliferative effect of secreted DD-FGF2. In the bottom wells, ASCs cells were plated at equal density. In transwell plates above these wells with a porosity of 0.4 μm, we seeded DD-FGF2 cells. The pore size of this transwell membrane allowed for the diffusion of soluble factors between the DD-FGF2 cells and ASCs, but prevented physical migration of the cells, allowing us to test the paracrine effect of secreted DD-FGF2 on ASC proliferation. The co-culture plates were exposed to varying concentrations of Shield-1.
Higher concentrations of Shield-1 significantly increased the proliferative capacity of the mouse ASCs co-cultured with the DD-FGF2 secreting cells in a dosedependent manner as compared to our control groups (Fig. 1E) .
The mitogenic activity of mouse ASCs was then correlated with activation of the Erk signaling pathway.
The Erk signaling pathway is a known downstream mediator of the mitogenic effects of FGF-2 (25). Mouse ASCs that had been cocultured with DD-FGF2 cells treated with Shield-1 exhibited dramatically greater amount of Erk pathway activation, as shown by the greater amount of Erk phosphorylation with Shield-1 treatment (Fig. 1F) .
In vivo regulation of FGF-2 secretion-Next we sought a model for demonstrating that chemical control of FGF-2 could promote in vivo skeletal healing by increasing the proliferation and eventual osteogenic differentiation of transplanted ASCs. Having shown that FGF-2 could be tunably and reversibly controlled in vitro, we employed this system for FGF-2 delivery in vivo in conjunction with our previously described mouse calvarial defect model. Critical sized (4 mm) defects were created in the parietal bone of adult, male CD-1 nude mice. Previously these defects have been bridged by bone over a 12-week period when implanted with two hundred thousand, mouse ASCs seeded on a hydroxy-apatite coated poly-lactic-co-glycolic acid (PLGA) scaffold (15) . We chose half the number of ASCs from our original study so that the osteogenic potential of these cells to heal a critical sized defect would not be demonstrated without a chemically controlled exogenous factor, in this case FGF-2.
We treated DD-FGF2 cells with mitomycin to render them incompetent for proliferation (Supplemental Data Fig. 1 ) and tested their Shield-1 long-term responsiveness in vitro (Supplemental Data  Fig. 2 ). We seeded a mixture of these mitomycin treated DD-FGF2 cells and GFP mouse ASCs in a 1:2 ratio (50,000 DD-FGF2 cells:100,000 ASCs) onto apatitecoated PLGA scaffolds. In essence, the DD-FGF2 cells served as feeder cells or "factories", secreting FGF-2 to their neighboring mouse ASCs when treated with Shield-1. This construct was then implanted into critical-sized, calvarial defects of adult, male CD-1 nude mice. Our treatment groups (n=4-6 mice/group) consisted of mice that were administered with intraperitoneal injections of Shield-1 every other day for first 12 weeks (Continuous), every fourth day for the first 12 weeks (Pulsatile), every other day for the first three weeks (Early), or every other day during weeks 4-6 (Middle) (Fig. 2A) . No gross changes in mouse behavior, grooming, feeding, or weight loss, were associated with Shield-1 administration.
Over a twenty-week period, we found that animals implanted with ASCs and DD-FGF2 cells and treated with Shield-1, formed more bone within calvarial defects than control groups by volumetric bone densitometric measurements from computed tomography (CT) scans. At twenty weeks, there was approximately two-fold more bone formation in the calvarial defects between animals treated with Shield-1 than control groups as shown by 3D rendered CT scans from representative animals (Fig. 2B) . Furthermore, the pattern of Shield-1 treatment, whether it be an early pulse, middle pulse, pulsatile exposure, or continuous exposure, all resulted in comparable amounts of bone formation after 20 weeks (Fig. 2C) .
Pentachrome histology from representative animals at 2 and 20 weeks was used to corroborate our CT findings (Fig. 3A) . We found that animals implanted with ASCs and DD-FGF2 cells and treated with Shield 1 demonstrated more bone formation than control groups, as demonstrated by increased yellow staining. Additionally, we sought to confirm that FGF-2 levels were increased in the implanted scaffolds after Shield-1 treatment. We performed immunohistochemistry (IHC) for FGF-2 on histological sections of implanted scaffolds at two weeks from three representative animals. IHC revealed that animals treated with Shield-1 demonstrated increased FGF-2 staining within the scaffold when compared to animals which did not receive Shield-1 treatment (Fig. 3B ). As proliferating cell nuclear antigen (PCNA) staining can be used to measure cell proliferation, PCNA IHC was used to show that Shield-1 treatment groups also indicated more proliferation than control groups (Fig.  3C) .
DISCUSSION
Demonstrating chemical control of FGF-2 secretion for calvarial defect regeneration represents the first application of this system towards cellular based, skeletal tissue engineering efforts. This study demonstrates proof of principle the application of chemical control towards longitudinal delivery of important protein factors for tissue engineering purposes. We found that DD-FGF2 was highly regulated by Shield-1 in vitro and was functionally capable of causing ASC chemotaxis and proliferation. As ex-vivo preparation of engineered tissues advances, this system may be used to refine the dose and spatial delivery of proteins of interest.
All mouse groups that were implanted with ASCs and DD-FGF2 cells and treated with Shield-1 treatment exhibited increased levels of bone density relative to controls (Fig. 2C) . When both feeder cells and ASCs were implanted but not dosed with Shield-1, the bone density at the final time point was similar to controls where no ASCs were implanted. One plausible explanation for these observations is that Shield-1, regardless of the timing of administration, mobilizes enough FGF-2 to saturate the osteogenic potential of the wound site. Previous work has shown FGF-2 to bind avidly to heparin in the extracellular matrix, limiting its diffusion and protecting it from proteolysis (26-28). The similar increase in bone formation in response to FGF-2 exposure across the different groups of animals implanted with ASCs and DD-FGF2 cells, regardless of the temporal pattern of FGF-2 exposure, is most likely in part a reflection on the pharmacokinetics of FGF-2 in vivo, rather than a reflection of our delivery system in mouse models (9) . Notably, we used half the number of ASCs used by Cowan et al. shown to regenerate skull defects, so as not to obscure the effect of chemically driven FGF-2. These data do not argue that implanting ASCs with engineered feeder cells is better than implanting high numbers of ASCs alone. More generally, our method is a model for tissue engineering applications where a small molecule controlled protein of interest may modulate in vivo physiology in a predictable manner.
The molecular mechanism behind our observation of increased bone formation in vivo in groups exposed to FGF-2 remains an open question. Previous studies have clearly established the importance of FGF-2 in regulating osteogenesis. Although in vitro studies have presented varying effects of FGF-2 on osteogenic differentiation (20, 22, (29) (30) (31) (32) , it is well established that FGF-2 in vivo promotes bone formation (16, 18, (33) (34) (35) (17, 19) .
Conversely, the exogenous exposure of FGF-2 in vivo has consistently resulted in increased bone formation (18, (33) (34) (35) .
Potential explanations for the in vivo observation of increased bone formation in response to FGF-2 include increased proliferation of osteoprogenitors or increased bone formation by existing osteoblasts. In vitro analysis of calvarial cells has found FGF-2 to exert differentiation stage-specific effect, namely increased proliferation of immature cells and increased matrix mineralization of mature cells (36) . Similarly, in vivo assays have demonstrated application of FGF-2 to increase proliferation of osteoprogenitor cells (37) . Relevant to our study, we have previously found FGF-2 to have a mitogenic effect on mouse ASCs but also to preserve their osteogenic potential (20) . Exposure of mouse ASCs to FGF-2 increased their proliferative potential while increasing the expression of Runx2, suggesting FGF-2's role in expanding the osteoprogenitor population. In light of the evidence discussed above and our findings of increased proliferation as suggested by PCNA immunohistochemistry (Fig. 3C ) and increased bone formation as shown by Pentachrome staining (Fig. 3A) of mouse groups exposed to FGF-2, we suggest that our observation of increased bone formation may be due to increased proliferation of our implanted mouse ASCs. This expansion of osteoprogenitor cells among our implanted ASCs may explain the insensitivity of our model to different patterns of FGF-2 exposure.
One advantage of this system in vivo is that the systemic delivery of a small molecule can control the local release of a signaling factor. In the calvarial defect model, systemic delivery of Shield-1 causes the local release of FGF-2 as demonstrated by FGF-2 histology (Fig. 3B ). This may be important when access to the particular tissue is not amenable to local injection and when the systemic delivery of a protein of interest may be highly toxic or cause unwanted pathology. Notably, we observed no adverse effects of prolonged treatment with Shield-1 on the health of our mice and we have previously demonstrated via microrray studies that Shield-1 appears to be biologically inert in mammalian cells (9) .
With rapid advances in scaffold technology, the ability to spatiotemporally deliver proteins is becoming a fast reality. As such, the use of chemical control systems will be instrumental in defining parameters with which to design such "smart scaffolds." One disadvantage of this system for protein delivery is the use of retrovirus to create transgenic cells. It is well established that retroviral transduction carries with it the potential for oncogenesis (38) . Looking forward, advances in non-viral methods of gene delivery provide hope that gene and cell therapy may enter the clinical realm. In that event, chemical control of protein secretion may be used for therapeutic tissue engineering purposes.
Furthermore, the development of multiple, orthogonal DD systems with clinically approved chemical ligands (39) , may pave the way for unprecedented control of tissue formation through the modulation of relevant signaling proteins in multipotent cells. by guest on October 30, 2017 
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